US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose formulation could help defend the brand.